Engineered immune cells take on viruses in cancer patients
NCT ID NCT05101213
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing whether genetically modified T-cells can safely control viral infections in cancer patients with weakened immune systems. The T-cells are designed to target specific viruses like CMV, BK virus, or COVID-19. The study involves 30 participants and focuses on safety and feasibility, not yet on effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified virus-specific T-cells (CTLs)
What this could lead to
If successful, this could provide a new way to control dangerous viral infections in cancer patients who have weak immune systems, potentially reducing illness and death from these infections.
What could go wrong
This is a very early phase 1 trial with only 30 participants, so it is primarily testing safety and feasibility. The treatment may not work, and there could be side effects from the modified cells or the process of giving them.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact